Center for Voice and Swallowing, Department of Otolaryngology, Tufts Medical Center, Boston, Massachusetts, Pittsburgh, Pennsylvania, USA.
Laryngoscope. 2011 Feb;121(2):313-9. doi: 10.1002/lary.21258. Epub 2011 Jan 13.
OBJECTIVES/HYPOTHESIS: Studies have shown excellent results for 12-month post-injection augmentation data for calcium hydroxylapatite (CaHA) for glottal incompetence; however, the longevity of the material past one year was unknown. Our objective was to report the long-term effectiveness of CaHA as a vocal fold injectable by assessing data from a cohort of patients who underwent injection for glottal insufficiency.
Retrospective chart review.
Patients who underwent CaHA injection for glottal insufficiency of any etiology were considered for inclusion in the study. The change in Voice Handicap Index (VHI)-10 scores between preinjection scores and best postinjection scores as well as between the preinjection and the most recent VHI-10 scores were used as primary outcome measures to determine the persistence of benefit or the time to loss of benefit. Complications among the cohort were identified.
Ninety patients who underwent 108 vocal fold injections with CaHA were evaluated for inclusion. Twenty patients with 22 injections met the criteria for inclusion. Fourteen of 22 (64%) subjects showed loss of benefit of the CaHA material. The average length of benefit was 18.6 months, with a range of 8 to 36 months. Three complications were identified among the original cohort of 108 injections.
CaHA remains a safe and effective long-term vocal fold injectable with an average length of benefit of 18.6 months. Three complications were seen among 108 CaHA injections. CaHA is a long-term injectable with an excellent track record that does not appear to warrant concern for permanent or late complications.
目的/假设：研究表明，对于 12 个月后注射羟基磷灰石（CaHA）治疗声门不全的效果非常好；然而，该材料在一年后是否能长期保持效果尚不清楚。我们的目的是通过评估一组因声门不全接受注射治疗的患者的数据，报告 CaHA 作为声带注射剂的长期有效性。
回顾性图表审查。
任何病因导致声门不全而接受 CaHA 注射的患者均被认为符合纳入研究标准。使用嗓音障碍指数（VHI）-10 评分的变化作为主要的评估指标，包括注射前和最佳注射后的评分变化，以及注射前和最近一次 VHI-10 评分的变化，以确定获益的持久性或获益丧失的时间。同时，还确定了队列中的并发症。
共有 90 名接受 108 次 CaHA 声带注射治疗的患者接受了评估，其中 20 名患者的 22 次注射符合纳入标准。22 次注射中有 14 次（64%）患者出现 CaHA 材料获益丧失。CaHA 的平均获益时间为 18.6 个月，范围为 8 至 36 个月。在最初的 108 次 CaHA 注射中，发现了 3 种并发症。
CaHA 仍然是一种安全有效的长期声带注射剂，平均获益时间为 18.6 个月。在 108 次 CaHA 注射中，出现了 3 种并发症。CaHA 是一种长期有效的注射剂，具有良好的记录，似乎没有永久性或迟发性并发症的担忧。
